Oncology Medical News about tubulin-binding agent

Become a Member Today!
Register

Most Viewed Abstracts

1. Report Shows Shift in Starting Salaries for Physicians

2. Recommendations on the use of 18F-FDG PET in oncology

3. Taxane-based combinations as adjuvant chemotherapy of early breast cancer: a meta-analysis of randomized trials

4. Gene expression signatures, clinicopathological features, and individualized therapy in breast cancer

5. Sentinel node biopsy is important in mastectomy for ductal carcinoma in situ

Your Article Summary

See Latest Articles

(Click the title below to leave the MDLinx Network and go to the Journal's Website)

ABT-751, a novel tubulin-binding agent, decreases tumor perfusion and disrupts tumor vasculature
Anti-Cancer Drugs, 07/02/09

Luo Y et al. - The results show that ABT-751 is a tubulin-binding agent with antivascular properties. Microtubule disruption and morphological changes in vascular endothelial cells may be responsible, at least in part, for the dysfunction of tumor blood vessels after ABT-751 treatment.

<< Previous
Targeting the Bcl-2 family of proteins in Hodgkin lymphoma: in...

Next >>
Chemoprevention of metaplasia initiation and carcinogenic...

Triple-negative breast cancer—current status and future directions
Annals of Oncology, 11/16/09 Relevance Score: 45%

Use of remifentanil as a sedative agent in critically ill adult patients: a meta-analysis
Anaesthesia, 11/11/09 Relevance Score: 45%

Agents with inotropic properties for the management of acute heart failure syndromes. Traditional agents and beyond
Heart Failure Reviews, 11/03/09 Relevance Score: 45%

The Impact of Bittering Agents on Pediatric Ingestions of Antifreeze
Clinical Pediatrics, 10/26/09 Relevance Score: 45%

The role of urate and xanthine oxidase in vascular oxidative stress: future directions
Therapeutics and Clinical Risk Management, 10/07/09 Relevance Score: 45%